FRAPS BSc - Puma Biotechnology Pharmacovigilance, Affairs
| PBYI Stock | USD 3.23 0.09 2.87% |
Executive
FRAPS BSc is Pharmacovigilance, Affairs of Puma Biotechnology
| Age | 59 |
| Address | 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 |
| Phone | 424 248 6500 |
| Web | https://www.pumabiotechnology.com |
Puma Biotechnology Management Efficiency
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4232 %, meaning that it created $0.4232 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The Puma Biotechnology's current Return On Tangible Assets is estimated to increase to 0.13. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.26. As of now, Puma Biotechnology's Return On Assets are increasing as compared to previous years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christine Utter | PTC Therapeutics | 46 | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Diane Berry | Sarepta Therapeutics | N/A | |
| Lisa Sinclair | Arvinas | N/A | |
| Vimal Srivastava | Ultragenyx | 59 | |
| MS MBA | Kura Oncology | 50 | |
| Michael Morneau | Viking Therapeutics | 59 | |
| Samuel Wadsworth | Ultragenyx | 76 | |
| Jenn Snyder | 2Seventy Bio | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Francesca Nolan | Sarepta Therapeutics | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Kerri Jensen | 2Seventy Bio | N/A | |
| Paul JD | Ultragenyx | N/A | |
| Vicki Eatwell | 2Seventy Bio | N/A | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Ronald MD | Arvinas | 58 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| Randy Teel | Arvinas | 44 | |
Management Performance
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0973 |
Puma Biotechnology Leadership Team
Elected by the shareholders, the Puma Biotechnology's board of directors comprises two types of representatives: Puma Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Puma. The board's role is to monitor Puma Biotechnology's management team and ensure that shareholders' interests are well served. Puma Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Puma Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Ludwig, Chief Officer | ||
| Maximo Nougues, CFO Officer | ||
| Alan Auerbach, Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee | ||
| Alvin Pharmd, Chief Officer | ||
| FRAPS BSc, Pharmacovigilance, Affairs | ||
| Mariann Ohanesian, Senior Director, Investor Relations | ||
| Bo Chao, Senior Development |
Puma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Puma Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0973 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 148.2 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Shares Owned By Insiders | 15.14 % | ||||
| Shares Owned By Institutions | 67.70 % | ||||
| Number Of Shares Shorted | 2.98 M | ||||
| Price To Earning | 18.52 X |
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.